Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Gammadelta Therapeutics Limited is currently managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners and 4 distinct art units, indicating a broad and diversified prosecution strategy. This variety suggests that the company is pursuing multiple distinct technological paths or applications within the biotech sector simultaneously. The involvement of 4 distinct art units means the company must navigate the specific standards and examination styles of four different technical groups.
The busiest examiner, STEPHENS, AMELIA CAROLE, is responsible for 1 busiest examiner pending action. Because the 4 pending office actions are spread across 4 distinct examiners, no single examiner has a dominant influence over the portfolio's overall progress. This distribution requires a more complex and varied approach to its patent prosecution compared to more centralized portfolios. The company's 4 pending office actions benefit from being reviewed by 4 distinct examiners, providing multiple opportunities for success across the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEPHENS, AMELIA CAROLE | 1 | 85.7% | +33.3% |
| MIANO, JOSEPH PAUL | 1 | 36.0% | +63.3% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 57.8% | +30.2% |
| MARTIN, PAUL C | 1 | 41.8% | +21.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044195 | IMMUNOTHERAPY COMPOSITION | STEPHENS, AMELIA CAROLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17292414 | METHODS FOR ISOLATING AND EXPANDING CELLS | MARTIN, PAUL C | 17d overdue |
| 18044195 | IMMUNOTHERAPY COMPOSITION | STEPHENS, AMELIA CAROLE | — |
| 17998766 | METHODS FOR ISOLATING GAMMA DELTA T CELLS | MIANO, JOSEPH PAUL | — |
| 17904890 | EX VIVO GAMMA DELTA T CELL POPULATIONS | ALSOMAIRY, SARAH ABDOALATIF | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1631 | 1 |
| 1646 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18044195 | IMMUNOTHERAPY COMPOSITION | STEPHENS, AMELIA CAROLE | 1645 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 06, 2023 |
| 17998766 | METHODS FOR ISOLATING GAMMA DELTA T CELLS | MIANO, JOSEPH PAUL | 1631 | §103Other | Final Rejection | — | Pending | Nov 14, 2022 |
| 17904890 | EX VIVO GAMMA DELTA T CELL POPULATIONS | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §112DP | Non-Final OA | — | Pending | Aug 24, 2022 |
| 17292414 | METHODS FOR ISOLATING AND EXPANDING CELLS | MARTIN, PAUL C | 1653 | §103Other | Final Rejection | 17d overdue | Pending | May 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial